Myocarditis Therapy with IL-1 inhibitor (MYTH-1): a double-blind, phase IIa, placebo-controlled, randomized clinical trial to evaluate the efficacy and safety of anakinra in addition to standard of care for the treatment of virus-negative myocarditis

INTERVENTION: Product Name: , Product Code:SCP183367, Pharmaceutical Form: , Other descriptive name: , Strength: CONDITION: endomyocardial biopsy (EBM)‐proven virus‐negative myocarditis Therapeutic area: Diseases [C] ‐ Cardiovascular Diseases [C14] INCLUSION CRITERIA: 18 Years to 75 Years, Myocarditis defined by cardiac magnetic resonance (according with Lake Louise Criteria) and virus‐negativity defined by on endomyocardial biopsy., Any impairment of left ventricular ejection fraction (LV‐EF) <55% on Trans Thoracic Echocardiography., Ability to sign an informed consent.